Summarized by Masters of Longevity from Longevity Technology.
A news article previewing a clinical trial update about a liver-regeneration drug reaching an independent safety milestone; it outlines next steps and study design.
Key Takeaways
- The first patient in the second pilot completed a 28-day darizmetinib dosing period after major liver resection.
- No treatment-related serious adverse events were reported in the study to date.
- Regulators including the FDA, EMA and Israel Ministry of Health reviewed and authorised the study's seamless Phase 1b to Phase 2a design.
